CXCL12 and chronic myelogenous leukemia, BCR-ABL1 positive: CXCL12 deletion from MSCs, moreover, increase LSC elimination by TKI treatment, thus favoring the eradication of CML LSCs and reducing the probability of CML persistence and recurrence.